EMA Product-Specific Bioequivalence Guidance

The EMA Product-Specific Bioequivalence Guidance is a regulatory reference resource published by the EuRoPEan Medicines Agency. Rather than being a Generative AI product, it is a scientific guidance collection that supports teams working on generic drug development, CLInical phArmacology, and regulatory submissions in the European Union. It is best understood as an authoritative documentation hub that Professionals consult when planning bioequivalence studies for specific ACTive substances.

What it does

The resource gathers product-specific bioequivalence requirements adopted by the EMA's ComMITtee for Medicinal Products for Human Use. Each entry describes the study design, conditions, and acceptance criteria regulators expect for a particular medicinal product. The guidance is organized under the EMA's clinical pharmacology and pharmacokinetics scientific guidelines SECtion and is updated as new product-specific guidance is adopted or revised.

Key capabilities

• ProvIDEs substance-by-substance bioequivalence study recommendations for EU marketing authorization submissions.
• Covers study design considerations such as dose selection, fasting or fed conditions, and analyte measurement.
• Supports planning for clinical trial protocols and regulatory dossiers.
• Offers a centralized, officially mAIntained reference that reduces ambiguity during generic Product Development.
• Links into broader EMA scientific guideline areas for pharmacokinetics and clinical pharmacology.

Who it is for

This resource is most relevant to regulatory affairs specialists, clinical pharmacologists, pharmacokinetics scientists, generic drug developers, contract research organizations, and academic researchers studying bioequivalence. It is also useful for consultants who advise sponsors on European submission strategy. It is not aimed at General consumers or at users seeking creative AI applications.

How to get started

1. Open the EMA website and navigate to the scientific guidelines section for clinical pharmacology and pharmacokinetics.
2. Locate the product-specific bioequivalence guidance area.
3. Identify the active substance relevant to your development program.
4. Review the recommended study design and acceptance criteria, and confirm the current veRSIon and adoption date.
5. Cross-check the guidance against the latest APPlicable EMA regulatory documents before finalizing a protocol.

Pricing and access caveat

Access to the guidance appears to be free and publicly available through the EMA website, with no subscription indicated. Availability, document versions, and updates may vary over time, so users should verify the current status of any guidance directly with the EMA. Regulatory requirements can change, and this guidance should not substitute for fORMal regulatory advice or direct consultation with authorities.